Tagged Articles

weight loss drug 21 articles

Diet drug Contrave linked to cases of loss of consciousness, abuse

The Food and Drug Administration (FDA) are looking into cases of loss of consciousness and abuse identified during a postmarketing review with the anti-obesity drug Contrave. Contrave was approved by the FDA September 2014. It is a combination of the alcohol and opioid dependence treatment naltrexone hydrochloride and the antidepressant bupropion hydrochloride. Contrave is intended as a treatment option for chronic weight management in obese patients (those with a BMI of 30 or greater) or overweight patients (those with a BMI of 27 or greater) who have at least one weight-related condition such as high blood pressure, type 2 diabetes, ... Read More

Heart safety trial on diet drug Contrave halted prematurely

Takeda Pharmaceuticals Co. is threatening to sever its partnership with Orexigen Therapeutics Inc. after a safety study on the diet drug Contrave was halted because trial data was released prematurely. Orexigen had announced last March – when only about 25 percent of the data was in – that early data from a clinical trial to evaluate cardiovascular outcomes with Contrave showed patients taking the obesity medication had a reduction in heart-related deaths. The information was released as part of a patent application. The Food and Drug Administration (FDA) criticized Orexigen for releasing the information too soon, saying the trial’s integrity had ... Read More

Drug company tests high doses of type 2 diabetes drug Victoza as possible weight loss treatment

A high-dose version of the type 2 diabetes drug Victoza is being tested as a new diet drug, and studies show it can melt up to 10 percent of body mass. Victoza is currently available in 1.2 mg and 1.8 mg doses to help drive down blood sugar levels in type 2 diabetics. Pre-market studies on the drug already identified weight loss as a side effect of the medication. Thus, the drug’s maker, Novo Nordisk, decided to see if higher doses of Victoza could lead to greater weight loss in obese people without the disease. Novo Nordisk began testing the ... Read More

Type 2 diabetes drug Victoza tested as potential diet drug

The type 2 diabetes drug Victoza (liraglutide) can help overweight and obese people without diabetes lose weight, according to a new multinational clinical trial, but the drug comes with some risks. Victoza, an injectable drug in a class of diabetes medications known as glucagonlike peptide-1 (GLP-1) agonist, was approved by the Food and Drug Administration (FDA) in January 2010 to help lower blood sugar levels in people with type 2 diabetes. In an effort to expand the indication to non-diabetics who are overweight, the medication was pitted against a placebo and the currently marketed anti-obesity drug Qsymia, a combination of ... Read More

Alli weight loss pills recalled due to potential tampering

GlaxoSmithKline (GSK) is recalling all of its Alli weight loss products in the United States and Puerto Rico after numerous reports across several states that packages may have been tampered with and may contain counterfeit pills. GSK received reports from customers in seven states that bottles of Alli tablets and capsules were not Alli. The counterfeit pills inside the bottles were in various shapes and colors. Some of the bottles inside the outer carton were missing labels and had tamper-evident seals that were not authentic. All of the tampered with products were purchased in retail stores. Alli is an over-the-counter ... Read More

Drug company Orexigen conducts tests on experimental diet pill Contrave

Interim analysis of Orexigen Therapeutics’ experimental weight loss drug Contrave showed successful results, setting the stage for possible marketing approval by United States drug regulators by June 2014. The Food and Drug Administration (FDA) rejected Orexigen’s bid for approval in February 2011, saying it needed more data from a large-scale study on the long-term effects the obesity medication has on the heart. Contrave is a combination of two already approved medications – bupropion, which is the active ingredient in the antidepressant Wellbutrin, and the anti-addiction drug naltrexone. Contrave is designed to influence the hypothalamus in in order to decrease food ... Read More

Diet pill Qsymia may reduce risk of type 2 diabetes in obese patients

Obese patients who took the new weight loss drug Qsymia were more than 70 percent less likely to develop type 2 diabetes compared to patients who were taking a placebo, according to a late-stage clinical trial. Type 2 diabetes is a chronic condition in which the body does not produce any or enough insulin, causing unstable blood sugar levels. Being overweight significantly increases the risk of developing the disease. Qsymia was approved last year and became the first weight loss pill to be approved for sale in the United States in 13 years. The drug is intended for people with a ... Read More

European drug advisors reject Qsiva (Qsymia) diet drug based on safety concerns

Advisors for the European Union’s health agency has again recommended against approving the new weight loss drug Qsiva, made by Vivus Inc. The Committee for Medicinal Products for Human Use raised concerns about the cardiovascular safety of the drug, saying it would need more data proving its safety before it would reconsider its rejection. Qsiva is a combination of two FDA-approved drugs – phentermine, an appetite suppressant, and topiramate, used to treat epilepsy and migraines. Phentermine was part of the fen-phen diet drug cocktail that was popular in the 1990s, but was pulled from the market after studies showed the ... Read More

Tainted dietary supplements seized by federal agents

Tainted dietary supplements made by Globe All Wellness (Globe All), in Hollywood, Fla., were seized by U.S. Marshals acting on behalf of the Food and Drug Administration (FDA) because the products contain an undisclosed active pharmaceutical ingredient and may be unsafe. Several of the seized products contain sibutramine hydrochloride (sibutramine), the active ingredient in the obesity drug Merida. In December 2010, the FDA pulled Meridia from the U.S. market after clinical data showed the drug increased the risk for heart attacks and strokes. Globe All claims its products can lower blood pressure and cholesterol, as well as improve other health ... Read More

Drug company wants to speed review process for new diet drug Contrave

Orexigen Therapeutics Inc. is hoping the Food and Drug Administration (FDA) will grant its request to speed up the review process for its obesity drug Contrave. The agency rejected the weight loss drug in February 2011, saying it needed data from a large-scale study on the long-term cardiovascular effects associated with the medication before approval would be granted. Contrave is a combination of two medications already approved by the FDA – bupropion, which is the active ingredient in the antidepressant Wellbutrin, and the anti-addiction drug naltrexone. Contrave is designed to influence the hypothalamus in order to decrease food intake over ... Read More